Wellington Management Group LLP Has $2.66 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Wellington Management Group LLP lowered its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVAFree Report) by 26.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 254,660 shares of the company’s stock after selling 89,927 shares during the quarter. Wellington Management Group LLP’s holdings in Teva Pharmaceutical Industries were worth $2,659,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Blue Trust Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 92.3% during the 4th quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock worth $46,000 after purchasing an additional 2,180 shares in the last quarter. Psagot Value Holdings Ltd. Israel acquired a new stake in Teva Pharmaceutical Industries during the fourth quarter worth about $57,000. Desjardins Global Asset Management Inc. increased its holdings in Teva Pharmaceutical Industries by 15.2% in the 4th quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock valued at $85,000 after buying an additional 1,070 shares during the period. Schechter Investment Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $117,000. Finally, DGS Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $119,000. Institutional investors own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 519,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the transaction, the director now directly owns 981,000 shares of the company’s stock, valued at approximately $16,706,430. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Vikki L. Conway sold 15,219 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $16.74, for a total value of $254,766.06. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Roberto Mignone sold 519,000 shares of the company’s stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the sale, the director now directly owns 981,000 shares in the company, valued at approximately $16,706,430. The disclosure for this sale can be found here. Insiders sold 549,719 shares of company stock worth $9,353,736 over the last three months. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $16.25 on Monday. The stock’s 50-day moving average is $15.99 and its 200-day moving average is $13.71. Teva Pharmaceutical Industries Limited has a 1-year low of $7.42 and a 1-year high of $17.69. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.20. The stock has a market cap of $18.41 billion, a P/E ratio of -39.63, a price-to-earnings-growth ratio of 1.54 and a beta of 0.91.

Teva Pharmaceutical Industries (NYSE:TEVAGet Free Report) last posted its earnings results on Wednesday, May 8th. The company reported $0.46 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.03). Teva Pharmaceutical Industries had a positive return on equity of 37.33% and a negative net margin of 2.88%. The business had revenue of $3.82 billion for the quarter, compared to analyst estimates of $3.70 billion. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, June 5th. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 20th. Bank of America upped their price objective on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, May 30th. Piper Sandler reiterated an “overweight” rating and issued a $20.00 target price (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 13th. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price for the company in a report on Friday, March 8th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

Read Our Latest Stock Analysis on TEVA

Teva Pharmaceutical Industries Profile

(Free Report)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Read More

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVAFree Report).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.